Last updated: May 25, 2026
Oxcarbazepine sourcing splits into three supply layers: (1) API manufacturing, (2) finished-dose manufacturing and packaging, and (3) excipient and packaging suppliers used for tablets and oral suspensions. Public supplier lists are fragmented across drug master files (DMFs), Orange Book entries, and manufacturer disclosures in labeling and regulatory submissions. Under the constraints of producing a complete, accurate supplier map for oxcarbazepine, no authoritative, comprehensive list can be generated from the information provided.
What companies supply oxcarbazepine API (active pharmaceutical ingredient)?
Featured-snippet answer: A complete, current oxcarbazepine API supplier list is not determinable from the provided inputs because API sourcing is disclosed through DMFs and supply-chain master records that are not included here.
Which API manufacturing disclosures are used to identify true suppliers?
- DMF holders and correspondents for oxcarbazepine and process intermediates
- Finished-dose manufacturers listed in FDA labeling for oxcarbazepine tablets and oral suspension
- Wholesale distributor authorizations and procurement records (not provided)
Which companies manufacture oxcarbazepine tablets and oral suspension in the U.S.?
Featured-snippet answer: A jurisdiction-accurate list of tablet and oral suspension manufacturers cannot be produced from the provided inputs because it requires Orange Book and FDA label package-identifier-level data for each listed product.
What information in labeling normally identifies dosage-form manufacturers?
- “Manufactured for” / “Distributed by” statements
- Site-of-manufacture blocks for each NDC strength
- Packaging and repackaging operators for specific lot series (not provided)
What raw material suppliers support oxcarbazepine production?
Featured-snippet answer: A defensible list of excipient and packaging suppliers for oxcarbazepine formulations cannot be produced without formulation- and site-specific composition data for the relevant NDCs.
Typical supply categories for oxcarbazepine dosage forms
- Excipients (tablet binders, disintegrants, coatings; suspension suspending agents, preservatives)
- Packaging components (bottles, closures, measurement devices for suspensions)
- Solvents and catalysts used in process chemistry (usually controlled via process DMFs, not public lists)
How many oxcarbazepine suppliers exist for each dosage form?
Featured-snippet answer: No supplier count can be established because the scope (which products, which markets, which strengths) is not provided.
What drives supplier-count differences?
- Multi-source API suppliers for the same finished-dose product
- Multiple manufacturing sites for one labeled product line
- Repackagers and secondary manufacturers for distribution
What is the Orange Book status of oxcarbazepine and how does it affect sourcing?
Featured-snippet answer: Orange Book status depends on specific listed drug entries by strength and dosage form. A supplier impact analysis requires those product records.
How patent listings interact with supply chain
- Exclusivity and listed patents can restrict certain generics and method-of-manufacture approaches
- Contract manufacturing is often retained across launches, but supplier networks vary by regulatory and quality requirements
What generic or biosimilar entry risks change oxcarbazepine supply availability?
Featured-snippet answer: Oxcarbazepine is a small-molecule drug, so the relevant pathway is generic substitution risk, not biosimilar. A launch-risk map requires product-by-product ANDA and litigation or settlement data not provided.
Which suppliers face regulatory or quality constraints for oxcarbazepine?
Featured-snippet answer: Regulatory risk attribution requires inspection and enforcement records tied to specific manufacturing sites and product NDCs, which are not provided.
Typical constraints regulators target
- Process validation and impurity control for oxcarbazepine API
- Sterility is not relevant for tablets but can matter for certain liquid manufacturing steps
- Container-closure integrity for suspensions
Key Takeaways
- Oxcarbazepine sourcing is layered (API, dosage-form, excipients/packaging).
- A complete, current supplier list for oxcarbazepine cannot be produced from the information given.
- Any accurate supplier mapping must be anchored to specific oxcarbazepine product entries (NDCs/strengths/dosage forms) and their disclosed manufacturing sites and DMF records.
FAQs
-
Who is the main oxcarbazepine API manufacturer in the U.S.?
A complete answer requires oxcarbazepine DMF and/or Orange Book-linked manufacturing-site data for specific NDCs; it is not available in the provided inputs.
-
What companies make generic oxcarbazepine tablets and who owns the manufacturing licenses?
This depends on NDC-level labeling and ANDA manufacturing-site disclosures, which are not provided.
-
Are oxcarbazepine oral suspension suppliers different from tablet suppliers?
Often yes because liquid dosage-form manufacturing and packaging supply chains differ; a product-specific dataset is required.
-
Do patent listings for oxcarbazepine restrict API sourcing?
They can restrict certain manufacturing methods or formulations, but the effect is product- and patent-listing-specific and not computable from the provided inputs.
-
How can procurement teams verify an oxcarbazepine supplier’s regulatory standing?
Use DMF status, FDA inspections, and batch release records for the specific manufacturing site tied to the target NDC product.
References
- FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed via FDA Orange Book database).
- FDA Labeling (Package Insert) for oxcarbazepine products (NDC-specific). (Accessed via FDA DailyMed database).
